Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

<< Previous

Bullboard Posts

Next >>

Post by bmreedon Nov 21, 2022 11:36am

232 Views

Post# 35115473

Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

Webinar - Antibe Therapeutics $ATE w/ CEO Dan Legault

Mon, November 21 at 4:15pm ET / 1:15pm PT

Q&A with Radius Research

Register Here - https://us02web.zoom.us/webinar/register/5216686324941/WN_NEICOjy7TOCAAlEzN3441w

CEO Dan Legault will be providing a corporate update, including the progress of its lead drug otenaproxesul, targeting acute pain, as well as updates on ATB-352 and its inflammatory bowel disease (IBD) program.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?